Brief: Scholar Rock Holding Corporation - ISEMBYLD US Commercial Launch Underway Product Available To Ship In Coming Days
11/09/2026 23:26
BRIEF-Scholar Rock Holding Corporation - ISEMBYLD US Commercial Launch Underway Product Available To Ship In Coming Days Sept 11 (Reuters) - Scholar Rock Holding Corporation SRRK.O:
SCHOLAR ROCK ANNOUNCES FDA APPROVAL OF ISEMBYLD™ (APITEGROMAB-MSTN), THE FIRST AND ONLY MUSCLE-TARGETED TREATMENT FOR CHILDREN AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA)
SCHOLAR ROCK HOLDING CORPORATION - ISEMBYLD U.S. COMMERCIAL LAUNCH UNDERWAY; PRODUCT AVAILABLE TO SHIP IN COMING DAYS
Source text: ID:nBw7vC3W0a
Further company coverage: SRRK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up